News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important To Cancer Immunotherapy Research


4/7/2014 9:38:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb). Recent reports have shown PD-L1 to be up-regulated on the surface of tumor cells, implicating this protein as one of the factors that allows tumors to evade the immune system. CST’s PD-L1 Rabbit mAb is an important addition for researchers studying tumor immunology and potential approaches to immunotherapy for melanoma, lung, ovarian, renal, prostate, and other cancers. Clinical researchers are evaluating antibodies to PD-L1 as potential cancer biotherapeutics (Brahmer, J.R., et al. (2012) New Engl J Med 366,2455-65).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES